News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Victory Pharma, Inc. Announces FDA Accepts MGX006 NDA for Review


7/13/2009 8:49:06 AM

SAN DIEGO, July 13 /PRNewswire/ -- Victory Pharma, Inc. ("Victory") announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for Victory's lead investigational rug, MGX006. If approved, MGX006 will provide patients and healthcare providers the advantage of a proven antiemetic agent combined with a proprietary formulation ideally suited for the treatment of nausea and vomiting.

Approximately 25 million prescriptions are written annually in the U.S. for anti-emetic therapeutics. The vast majority of these prescriptions are for traditional, oral solid drug formulations, which can be problematic among patients with emesis.

About Victory Pharma

Founded in 2003, Victory Pharma, Inc. is a privately held specialty pharmaceutical company headquartered in San Diego, CA focused on acquiring, developing, and marketing products to treat pain and related conditions. Victory markets its lead product, NAPRELAN(R) (naproxen sodium) Controlled-Release Tablets and other pain products to pain management specialists, rheumatologists, orthopedic surgeons, and selected primary care physicians through its physician office-based field sales force. Victory is also developing proprietary products for the treatment of chronic pain and common opiate- induced side effects Further information regarding Victory Pharma is available at www.victorypharma.com.

SOURCE Victory Pharma, Inc.

CONTACT: David J. Parker, Chief Financial Officer of Victory Pharma, Inc.,
+1-858-720-4524

Web site: http://www.victorypharma.com/


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES